trial · primary record
FB102
Vitiligo
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 64 |
| Primary completion | 2026-12-31 |
| Primary endpoint | Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102 |
| Registry ID | NCT06905873 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:24.424Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06905873
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.